0.378

0.85% 0.0032

After Hours: .38 0.002 +0.53%

Leap Therapeutics Inc (LPTX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Leap Therapeutics Inc stock is traded at $0.378, with a volume of 268.13K. It is up +0.85% in the last 24 hours and down -9.59% over the past month. Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Previous Close:

$0.3748

Open:

$0.38

24h Volume:

268.13K

Relative Volume:

0.13

Market Cap:

$15.66M

Revenue:

$1.50M

Net Income/Loss:

$-64.59M

P/E Ratio:

-0.2263

EPS:

-1.67

Net Cash Flow:

$-55.17M

1W Performance:

+3.68%

1M Performance:

-9.59%

6M Performance:

-87.32%

1Y Performance:

-83.98%

1-Day Range:

$0.3601

$0.40

1-Week Range:

$0.3601

$0.40

52-Week Range:

$0.2223

$4.79

Leap Therapeutics Inc Stock (LPTX) Company Profile

Name

Leap Therapeutics Inc

Sector

Healthcare (1178)

Industry

Biotechnology (671)

Phone

617 252 4343

Address

47 THORNDIKE STREET, CAMBRIDGE, MA

Employee

Twitter

@LeapTherapeutic

Next Earnings Date

2024-11-11

Latest SEC Filings

LPTX's Discussions on Twitter

Compare LPTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LPTX Leap Therapeutics Inc	0.378	15.30M	1.50M	-64.59M	-55.17M	-1.67
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	441.85	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.16	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	489.52	64.44B	14.09B	4.50B	2.96B	39.28

Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-29-25	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Oct-04-21	Initiated	Mizuho	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
Jun-29-20	Initiated	Piper Sandler	Overweight
Feb-11-20	Initiated	Robert W. Baird	Outperform
Nov-15-19	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-13-19	Resumed	Raymond James	Outperform
Mar-07-17	Initiated	Ladenburg Thalmann	Buy

View All

Leap Therapeutics Inc Stock (LPTX) Latest News

May 28, 2025

Leap Therapeutics Reports Increased Q1 Losses - TipRanks

May 28, 2025

May 22, 2025

Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace

May 22, 2025

May 21, 2025

Metastatic Colorectal Cancer Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025

May 20, 2025

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

May 20, 2025

May 17, 2025

HC Wainwright Issues Optimistic Outlook for LPTX Earnings - Defense World

May 17, 2025

May 13, 2025

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire

May 13, 2025

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

May 13, 2025

Cash-strapped Cambridge cancer biotech cuts 50% of its staff - NBC Boston

May 13, 2025

Cash-strapped Cambridge cancer biotech halves workforce - The Business Journals

May 13, 2025

Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' - Fierce Biotech

May 13, 2025

Leap Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

Leap Therapeutics Q1 Net Income USD -15.435 Million - marketscreener.com

May 13, 2025

Leap Therapeutics Reports First Quarter 2025 Financial Results | - GuruFocus

May 13, 2025

Leap Therapeutics Reports First Quarter 2025 Financial Results - Citizen Tribune

May 13, 2025

Leap TherapeuticsAnnounces 50% Workforce Reduction In Strategic RestructuringSEC Filing - marketscreener.com

May 13, 2025